- Home
- RGNX vs LRMR Comparison
RGNX vs LRMR Comparison
Compare RGNX & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- LRMR
- Stock Information
- Founded
- RGNX 2008
- LRMR N/A
- Country
- RGNX United States
- LRMR United States
- Employees
- RGNX N/A
- LRMR N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- RGNX Health Care
- LRMR Health Care
- Exchange
- RGNX Nasdaq
- LRMR Nasdaq
- Market Cap
- RGNX 372.1M
- LRMR 426.9M
- IPO Year
- RGNX 2015
- LRMR N/A
- Fundamental
- Price
- RGNX $7.57
- LRMR $3.43
- Analyst Decision
- RGNX Strong Buy
- LRMR Strong Buy
- Analyst Count
- RGNX 12
- LRMR 8
- Target Price
- RGNX $35.55
- LRMR $19.63
- AVG Volume (30 Days)
- RGNX 1.8M
- LRMR 624.9K
- Earning Date
- RGNX 02-25-2025
- LRMR 03-13-2025
- Dividend Yield
- RGNX N/A
- LRMR N/A
- EPS Growth
- RGNX N/A
- LRMR N/A
- EPS
- RGNX N/A
- LRMR N/A
- Revenue
- RGNX $84,327,000.00
- LRMR N/A
- Revenue This Year
- RGNX $2.92
- LRMR N/A
- Revenue Next Year
- RGNX $256.82
- LRMR N/A
- P/E Ratio
- RGNX N/A
- LRMR N/A
- Revenue Growth
- RGNX N/A
- LRMR N/A
- 52 Week Low
- RGNX $6.56
- LRMR $3.01
- 52 Week High
- RGNX $28.80
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- RGNX 45.51
- LRMR 31.67
- Support Level
- RGNX $6.98
- LRMR $3.21
- Resistance Level
- RGNX $7.70
- LRMR $3.54
- Average True Range (ATR)
- RGNX 0.54
- LRMR 0.22
- MACD
- RGNX 0.04
- LRMR 0.05
- Stochastic Oscillator
- RGNX 44.30
- LRMR 20.75
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.